Chemical & Engineering News

South Africa Air Purifiers Markets, Forecasts & Opportunities, 2018-2023 & 2023-2028

Retrieved on: 
Tuesday, July 18, 2023

The South Africa air purifier market is witnessing high demand due to the increased incidence of airborne diseases and the fast-rising pollution levels in various South African cities.

Key Points: 
  • The South Africa air purifier market is witnessing high demand due to the increased incidence of airborne diseases and the fast-rising pollution levels in various South African cities.
  • Thus, with the increasing air pollution level, people are installing air purifiers at residential and commercial places for better air quality.
  • Thus, with the rise in air pollution caused by mining activities, people prefer to buy air purifiers at their homes, thus, resulting in increased demand for air purifiers in the country.
  • Thus, with the increasing government initiatives, people in South Africa prefer to buy air purifiers for clean air at homes and commercial places.

Delix Therapeutics Appoints Aaron Koenig, MD as Chief Medical Officer

Retrieved on: 
Monday, June 12, 2023

BOSTON, June 12, 2023 /PRNewswire/ -- Delix Therapeutics (the "Company"), a neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological conditions, today announced the appointment of Dr. Aaron Koenig as Chief Medical Officer. Dr. Koenig will oversee Delix's clinical development programs, team build-out, and broader development strategy as the company advances its psychoplastogen platform of novel disease-modifying therapeutics for serious psychiatric, neurological, and neurodegenerative disorders.

Key Points: 
  • BOSTON, June 12, 2023 /PRNewswire/ -- Delix Therapeutics (the "Company"), a neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological conditions, today announced the appointment of Dr. Aaron Koenig as Chief Medical Officer.
  • Dr. Koenig joins the company from Sage Therapeutics, where he served most recently as Vice President of Early Medical Science and helped design and oversee clinical-stage programs, including compounds targeting a range of neuropsychiatric and neurodegenerative and disorders.
  • "As Delix navigates its phase I trial for the novel compound DLX-001, Dr. Koenig's experience in early clinical development will be crucial to advancing our novel neuroplasticity-promoting therapeutics," said Delix Therapeutics Head of Research & Development Dr. Eliseo Salinas.
  • A non-hallucinogenic psychoplastogen, DLX-001 is the first of several psychoplastogens in the Delix platform to be approved for human trials.

Endpoints News Announces New Editorial Hires in Coverage Expansion

Retrieved on: 
Monday, March 27, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230327005055/en/
    “We’re thrilled to have Jaimy, Andrew and Ryan join the Endpoints News team at this time of rapid growth.
  • In the last few months, the Endpoints team has done challenging in-depth reporting, great feature stories, and phenomenal breaking news on the industry,” said Drew Armstrong, Executive Editor of Endpoints.
  • She has held a mix of editing and reporting roles, including on LinkedIn’s editorial team, where she developed #TheCheckup newsletter and video series.
  • Prior to the Globe, at Chemical & Engineering News he led coverage of Covid-19 vaccines, gene editing, and all things RNA.

Pioneering Delix Therapeutics Study Published in 'Science' Elucidates the Mechanism of Psychedelic-Induced Neuroplasticity

Retrieved on: 
Thursday, February 16, 2023

BOSTON, Feb. 16, 2023 /PRNewswire/ -- Delix Therapeutics (the "Company"), a neuroscience company developing novel disease-modifying, neuroplasticity-promoting therapeutics for psychiatric and neurological conditions, shared the findings of a new study published today in Science. The groundbreaking paper, authored by Delix Co-founder and Chief Innovation Officer David E. Olson, PhD, reveals the mechanism that causes serotonin and psychoplastogens to activate the 5-HT2A receptor in different ways.

Key Points: 
  • BOSTON, Feb. 16, 2023 /PRNewswire/ -- Delix Therapeutics (the "Company"), a neuroscience company developing novel disease-modifying, neuroplasticity-promoting therapeutics for psychiatric and neurological conditions, shared the findings of a new study published today in Science.
  • The study uncovers the fact that intracellular 5-HT2A receptors mediate the psychoplastogenic effects of psychedelics.
  • As serotonin cannot activate this population of receptors, the study might explain why serotonin-based therapeutics - such as SSRIs, commonly prescribed antidepressants – have different effects than psychedelics and other psychoplastogenic therapeutics.
  • The Delix team continues to advance its unique scientific and talent advantage at the forefront of central nervous system drug development," added Mark Rus, CEO of Delix Therapeutics.

Delix Therapeutics Partners With Cellectricon, Expressive Neuroscience and Expands Science Team To Accelerate Drug Discovery and Translatability

Retrieved on: 
Tuesday, February 14, 2023

BOSTON, Feb. 14, 2023 /PRNewswire/ -- Delix Therapeutics (the "Company"), a neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological conditions, today announced its collaboration with two partners that will help expedite the company's drug development pipeline. To further the company's mission to 'rewire the brain to heal the mind', Delix is also expanding its team of experts, including the addition of Alison Mungenast, PhD, as Senior Director of Neuroplasticity. As a multifunctional neuroscientist, Alison joins Delix from Sana Biotechnology where she managed the CNS cell therapy group working to advance therapeutic approaches to neurodegenerative disease.

Key Points: 
  • BOSTON, Feb. 14, 2023 /PRNewswire/ -- Delix Therapeutics (the "Company"), a neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological conditions, today announced its collaboration with two partners that will help expedite the company's drug development pipeline.
  • As a multifunctional neuroscientist, Alison joins Delix from Sana Biotechnology where she managed the CNS cell therapy group working to advance therapeutic approaches to neurodegenerative disease.
  • Delix recently inked a deal with Cellectricon , the Sweden-based collaborative services provider dedicated to advancing drug discovery with innovative approaches to in vitro research.
  • Through the partnership agreements, Delix will benefit from unique access to novel assays and capabilities developed with Expressive Neuroscience and Cellectricon.

Sudoc Selected by Biomimicry Institute as one of Top 10 Nature-Inspired Companies Addressing Environment Issues

Retrieved on: 
Wednesday, September 14, 2022

CAMBRIDGE, Mass., Sept. 14, 2022 /PRNewswire-PRWeb/ -- Sudoc, LLC ("Sudoc"), a new chemical industry company committed to environmental sustainability, has been selected as one of the top ten bioinspired startups for 2022 by the Biomimicry Institute to participate in this year's Ray of Hope Prize program. The Biomimicry Institute's annual program identifies the top ten nature-inspired startups worldwide and cultivates their growth by providing sustainable business training, communications support, and opportunities for non-dilutive funding. As part of its nomination, Sudoc will take part in an upcoming 10-week virtual accelerator program and compete to receive the $100,000 grand prize as well as additional equity-free funding.

Key Points: 
  • This game-changing chemistry sets Sudoc apart as a different kind of chemical company with a mission to reduce our planet's chemical burden.
  • We applaud Sudoc for their important work and look forward to supporting their journey to bring their bioinspired chemistry to market."
  • In November 2021, Sudoc was named a Top Ten Start-Up to Watch by leading industry publication, Chemical & Engineering News.
  • It is such an honor for our work to be recognized by the Biomimicry Institute."

Sudoc wins Fast Company award as a 2022 World Changing Idea for its groundbreaking sustainable chemistry that outperforms and removes toxic chemicals from the planet

Retrieved on: 
Wednesday, May 4, 2022

A Founder and CEO of Sudoc, Roger Berry, states "We are honored to be recognized by Fast Company and included among a prestigious group of companies contributing to a sustainable future. Sudoc's sustainable chemistry platform is the foundation for a series of brands – Dot, Neat, and Umo to start -- that promise to change how we think about cleaning products, water treatment solutions, waste pharmaceutical disposal, pesticides, and a range of other applications. This chemistry truly has the ability to reduce the chemical burden of our planet and every household. We are very proud that Fast Company has recognized the importance of this mission."

Key Points: 
  • CAMBRIDGE, Mass., May 4, 2022 /PRNewswire-PRWeb/ -- Sudoc, Inc ("Sudoc"), a new chemical industry company committed to environmental sustainability, has been recognized by Fast Company as a 2022 World Changing Idea.
  • Fast Company's World Changing Ideas program annually awards organizations, businesses, products, concepts, and policies that are generating innovation for the benefit of society and the planet.
  • Sudoc was selected for Fast Company's On the Rise category of World Changing Ideas.
  • With a mission to outperform toxic chemicals to remove them from our planet, Sudoc is a different kind of chemical company.

Sudoc selected by Chemical & Engineering News as one of 10 Start-Ups to Watch

Retrieved on: 
Monday, November 29, 2021

Sudoc is a different kind of chemical company, with a mission to outperform toxic chemicals to remove them from our planet.

Key Points: 
  • Sudoc is a different kind of chemical company, with a mission to outperform toxic chemicals to remove them from our planet.
  • A Founder and CEO of Sudoc, Roger Berry, states "We are honored to be recognized by the experts at Chemical & Engineering News as a start-up to watch in 2021.
  • Sudoc is founded on a new, sustainable chemistry and committed to the long-term well-being of our planet.
  • Sudoc is an innovative chemical industry startup developing a sustainable but powerful chemistry that can outperform toxic chemicals in many applications.

Factorial Energy Named One of 10 Chemistry Startups to Watch By Chemical & Engineering News

Retrieved on: 
Monday, November 22, 2021

WOBURN, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Factorial Energy (Factorial) has been named one of 10 chemical industry Startups to Watch by Chemical & Engineering News, the weekly newsmagazine of the American Chemical Society (ACS).

Key Points: 
  • WOBURN, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Factorial Energy (Factorial) has been named one of 10 chemical industry Startups to Watch by Chemical & Engineering News, the weekly newsmagazine of the American Chemical Society (ACS).
  • Factorial has developed breakthrough solid-state battery technology that addresses two key issues holding back widescale consumer adoption of electric vehicles: driving range, and safety.
  • FEST leverages a proprietary solid electrolyte material that enables safe and reliable cell performance with high-voltage and high-capacity electrodes at room temperature.
  • It is an honor to be recognized by Chemical & Engineering News for our innovation in solid-state battery technology, said Factorial Energy CEO Siyu Huang, Ph.D.

Jennifer L. Maclachlan of PID Analyzers, LLC, announced as recipient of two American Chemical Society Public Relations Awards

Retrieved on: 
Tuesday, October 26, 2021

The American Chemical Society (ACS) has recognized member Jennifer L. Maclachlan as the recipient of both the 2021 Helen M. Free Award for Public Outreach and the 2022 James T. Grady-James H. Stack Award for Interpreting Chemistry for the Public .

Key Points: 
  • The American Chemical Society (ACS) has recognized member Jennifer L. Maclachlan as the recipient of both the 2021 Helen M. Free Award for Public Outreach and the 2022 James T. Grady-James H. Stack Award for Interpreting Chemistry for the Public .
  • The ACS Committee on Public Relations and Communications (CPRC) presents the public outreach award annually to an ACS member whose outstanding achievements have improved public recognition and appreciation for the field of chemistry.
  • ACS awards the chemistry interpretation award annually to someone who has made noteworthy presentations to increase the publics understanding of chemistry.
  • The American Chemical Society (ACS) is a nonprofit organization chartered by the U.S. Congress.